Tissue Engineered Vessels: Research to Clinical Trials

Cardiovascular disease is the leading cause of mortality in the United States, and arterial bypass procedures are the primary treatment for patients with advanced disease. Many patients lack autologous tissue for a bypass, so there is a need for alternative small diameter vascular grafts. Tissue engineered vessels are an appealing approach to address the demand for a small diameter biological vascular graft. This presentation will review the progress of tissue engineered vessels from research to translation application as a vascular graft in human clinical trials.

Clay Quint, MD, PhD
Vascular Surgeon, South Texas Veterans Health Care System
Adjunct Assistant Professor of Surgery, UT Health San Antonio